H. Lee Moffitt Cancer Center and Research Institute: Skin Neoplasms trials

The registry lists 17 Skin Neoplasms studies with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor. 3 are open to participants now and 6 have results posted.

Early Phase 1 4Phase 1 2Phase 2 8No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCsRecruitingNCT07222995Not applicable
• Adaptive Therapy of Vismodegib in Advanced Basal Cell CarcinomaRecruitingNCT05651828Early Phase 1
• Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell CarcinomaRecruitingNCT04975152Phase 1
• Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell CarcinomaActive, not recruitingNCT04869137Phase 2Results posted
• Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma PatientsCompletedNCT04526730Phase 2Results posted
• Using MC1R Genotype to Impact Melanoma Risk BehaviorCompletedNCT03509467Not applicableResults posted
• Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell CarcinomaActive, not recruitingNCT03071406Phase 2Results posted
• Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell CarcinomaCompletedNCT02218164Phase 2Results posted
• Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets PtsCompletedNCT01701674Not applicableResults posted
• Exercise to Boost Response to Checkpoint Blockade ImmunotherapyActive, not recruitingNCT05358938Early Phase 1
• Study of Afatinib in Advanced Cutaneous Squamous Cell CarcinomaActive, not recruitingNCT05070403Phase 2
• Axitinib + Ipilimumab in Advanced MelanomaActive, not recruitingNCT04996823Phase 2
• IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma PatientsActive, not recruitingNCT04562129Phase 2
• Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant MelanomaActive, not recruitingNCT03543969Early Phase 1
• XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV MelanomaActive, not recruitingNCT02721459Phase 1
• Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic MelanomaCompletedNCT02652455Early Phase 1
• Biomarker Correlates of Hypoxia in Metastatic MelanomaWithdrawnNCT02061007Phase 2